VC
SABS icon

Vivo Capital’s SAB Biotherapeutics SABS Stock Holding History

Vivo Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5M Sell
7,299,909
-4,120,091
-36% -$15.3M 2.6% 16
2026
Q1 		$43.7M Hold
11,420,000
– – 3.64% 8
2025
Q4 		$42.7M Hold
11,420,000
– – 2.76% 11
2025
Q3 		$23M Buy
+11,420,000
New +$25.8M 1.85% 18

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Vivo Capital's SABS Position: Q2 2026 in Review

Vivo Capital reduced its SAB Biotherapeutics (SABS) stake by 36% in Q2 2026, selling an estimated $15.3M and leaving 7,299,909 shares worth $28.5M. The position accounts for 2.6% of the portfolio, ranked #16.

Vivo Capital first reported a position in SABS in Q3 2025 and has held it in 4 quarters since. The position peaked at $43.7M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Vivo Capital held 7,299,909 shares of SAB Biotherapeutics worth $28.5M as of Q2 2026.
  • Vivo Capital sold 4,120,091 SAB Biotherapeutics shares in Q2 2026, an estimated $15.3M.
  • SAB Biotherapeutics made up 2.6% of Vivo Capital's portfolio in Q2 2026, its #16 holding.
  • Vivo Capital first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • Vivo Capital's SAB Biotherapeutics position peaked at $43.7M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.